NCT02995291View on ClinicalTrials.gov

Reversing the Effects of 0.5% Bupivacaine

PHASE4CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

February 10, 2017

Primary Completion Date

May 15, 2019

Study Completion Date

September 15, 2019

Conditions
Anesthesia, Local
Interventions
DRUG

OraVerse

1.7ml OraVerse (0.4 mg phentolamine mesylate) will be injected once after the participants are found to be well anesthetized following an injection of 1.8ml Bupivacaine 0.5% (inferior alveolar nerve block). Oraverse will be injected at the same site Bupivacaine was injected.

DRUG

Saline Water (Control)

1.7ml saline water will be injected once after the participants are found to be well anesthetized following an injection of 1.8ml Bupivacaine 0.5% (inferior alveolar nerve block). The water will be injected at the same site Bupivacaine was injected.

Trial Locations (1)

B3H 4R2

Dalhousie University Faculty of Dentistry, Halifax

All Listed Sponsors
lead

Dalhousie University

OTHER

NCT02995291 - Reversing the Effects of 0.5% Bupivacaine | Biotech Hunter | Biotech Hunter